Gainers
- Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
- Silo Pharma, Inc. (NASDAQ: SILO) rose 105% to $10.46 in pre-market trading following uplisting to the Nasdaq.
- Biogen Inc. (NASDAQ: NASDAQ:BIIB) shares rose 39.7% to $276.32 in pre-market trading. Biogen and Eisai Co. announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.
- Prothena Corporation plc (NASDAQ: PRTA) rose 37.4% to $42.50 in pre-market trading in sympathy with Biogen.
- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) rose 29.8% to $6.10 in pre-market trading after gaining around 6% on Tuesday.
- Flora Growth Corp. (NASDAQ: FLGC) rose 17.9% to $0.8621 in pre-market trading after dropping 8% on Tuesday.
- MorphoSys AG (NASDAQ: MOR) rose 17.7% to $5.24 in pre-market trading.
- Longeveron Inc. (NASDAQ: LGVN) rose 16.9% to $4.71 in pre-market trading. Longeveron, last month, received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS)..
- AIM ImmunoTech Inc. (NYSE: AIM) rose 16.4% to $0.6750 in pre-market trading after declining around 7% on Tuesday.
- ASAP, Inc. (NASDAQ: WTRH) rose 12.1% to $0.1793 in pre-market trading after declining around 9% on Tuesday.
- Windtree Therapeutics, Inc. (NASDAQ: WINT) rose 12% to $0.35 in pre-market trading.
- BioVie Inc. (NASDAQ: BIVI) rose 11.8% to $2.64 in pre-market trading. BioVie recently announced topline results from an investigator-sponsored Phase 2 clinical trial of NE3107 for the treatment of Alzheimer's Disease, saying "vast majority of patients saw significant improvements in the Global Rating of Change."
- Locafy Limited (NASDAQ: LCFY) rose 10.5% to $0.42 in pre-market trading after declining around 6% on Tuesday.
- Cassava Sciences, Inc. (NASDAQ: SAVA) rose 10.2% to $50.90 in pre-market trading. Shares of companies with potential Alzheimer's treatments trading higher premarket in sympathy with Biogen.
- Quanterix Corporation (NASDAQ: QTRX) rose 9.2% to $8.80 in pre-market trading.
- Lilly and Company (NYSE: LLY) rose 7.7% to $335.00 in pre-market trading. Shares of companies with potential Alzheimer's treatments trading higher premarket in sympathy with Biogen.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Don’t forget to check out our premarket coverage here .
Losers
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) fell 34.8% to $3.99 in pre-market trading as the company reported pricing of public offering of common shares and warrants.
- iBio, Inc. (NYSE: IBIO) shares fell 31.6% to $0.2162 in pre-market trading after the company reported FY22 preliminary sales results and announced a 1-for-25 reverse stock split.
- Nano Labs Ltd (NASDAQ: NA) fell 23% to $2.45 in pre-market trading after the company priced its 2.08 million ADS public offering at $2.40 per ADS.
- Gamida Cell Ltd. (NASDAQ: GMDA) fell 21.4% to $1.54 in pre-market trading after the company priced 12.9 nm share public offering of common stock at $1.55 per share.
- Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) fell 14% to $0.5161 in pre-market trading after surging 19% on Tuesday.
- EZGO Technologies Ltd. (NASDAQ: EZGO) fell 13% to $0.40 in pre-market trading.
- Avenue Therapeutics, Inc. (NASDAQ: ATXI) fell 12.3% to $6.37 in pre-market trading. The stock has been volatile after the company last week announced a 1-for-15 reverse split and received meeting minutes from the FDA regarding a meeting conducted on August 9, 2022, for IV Tramadol.
- MFA Financial, Inc. (NYSE: MFA) shares fell 10.8% to $7.90 in pre-market trading after the company filed for mixed-securities shelf offering.
- Presto Automation, Inc (NASDAQ: PRST) fell 10.4% to $2.41 in pre-market trading. The company recently completed its previously announced business combination with Ventoux CCM Acquisition.
- MoneyLion Inc. (NYSE: ML) shares fell 8.3% to $1.00 in pre-market trading.
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) shares fell 7.9% to $1.05 in pre-market trading. Aquestive Therapeutics recently announced positive topline results from the EPIPHAST 2 trial for its AQST-109 epinephrine sublingual film.
- 9 Meters Biopharma, Inc. (NASDAQ: NMTR) fell 7.6% to $0.1980 in pre-market trading. 9 Meters Biopharma recently announced final results from the Phase 2 VIBRANT study and a successful End-of-Phase 2 meeting with the FDA for vurolenatide in short bowel syndrome.
- Deutsche Bank (ETR:DBKGn) Aktiengesellschaft (NYSE: DB) fell 6.8% to $7.20 in pre-market trading. CFTC ordered 11 financial institutions to pay over $710 million for recordkeeping, supervision failures for widespread use of unapproved communication methods.
- Sandstorm Gold Ltd. (NYSE: SAND) fell 6.6% to $5.20 in pre-market trading after the company announced an $80 million bought deal financing.
- Credit Suisse (SIX:CSGN) Group AG (NYSE: CS) fell 5% to $3.78 in pre-market trading. CFTC ordered 11 financial institutions to pay over $710 million for recordkeeping, supervision failures for widespread use of unapproved communication methods.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.